SCHEMBL29477241

SCHEMBL29477241

CN(C)c1ccnn1Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
P2RX7 Q99572 1/20 0.46
CYP19A1 P11511 1/20 0.46
TSHR P16473 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
HSD17B10 Q99714 3/20 0.43
HPGD P15428 2/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
ATM Q13315 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SLC9A1 P19634 1/20 0.42
GRM2 Q14416 1/20 0.42
RECQL P46063 1/20 0.42
IDO1 P14902 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4365345 0.76 TSHR (0.56) LMNAP2RX7CYP19A1TSHRL3MBTL1
SCHEMBL4361625 0.73 P2RX7 (0.56) P2RX7CYP19A1TSHRALDH1A1KDM4E
SCHEMBL19738044 0.73 MAPK1 (0.31) MAPK1
SCHEMBL17627023 0.73 P2RX7 (0.47) LMNAP2RX7CYP19A1TSHRL3MBTL1
SCHEMBL21721655 0.73 P2RX7 (0.47) LMNAP2RX7CYP19A1TSHRL3MBTL1
SCHEMBL568868 0.72 KDM4E (0.72) P2RX7CYP19A1TSHRALDH1A1KDM4E
SCHEMBL3607562 0.72 CYP19A1 (0.50) P2RX7CYP19A1TSHRALDH1A1KDM4E
SCHEMBL1628296 0.72 P2RX7 (0.50) P2RX7CYP19A1TSHRALDH1A1KDM4E
SCHEMBL15675375 0.72 CYP19A1 (0.50) LMNAP2RX7CYP19A1TSHRALDH1A1
SCHEMBL22951232 0.71 KDM4E (0.47) LMNAP2RX7CYP19A1TSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577255-B2 MDM2-based modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-03-17 US disclosed
US-20220127279-A1 MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577255-B2 MDM2-based modulators of proteolysis and associated methods of use MDM2, UBR4, UBE3A LMNA 2705/4885P2RX7 4535/4885CYP19A1 2935/4885
US-20220127279-A1 MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE MDM2, XIAP, TP53 LMNA 3084/4885P2RX7 4805/4885CYP19A1 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.